BidaskClub downgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a research note published on Tuesday, January 9th.
Several other brokerages have also recently issued reports on GWPH. Zacks Investment Research cut shares of GW Pharmaceuticals PLC- from a hold rating to a sell rating in a research note on Tuesday, December 26th. Cantor Fitzgerald set a $208.00 target price on shares of GW Pharmaceuticals PLC- and gave the stock a buy rating in a research note on Monday, December 4th. Bank of America lowered their target price on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a buy rating on the stock in a research note on Tuesday, November 14th. Goldman Sachs Group reaffirmed a neutral rating and set a $124.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Friday, October 6th. Finally, ValuEngine cut shares of GW Pharmaceuticals PLC- from a hold rating to a sell rating in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $148.78.
Shares of GW Pharmaceuticals PLC- (GWPH) opened at $133.30 on Tuesday. The company has a market cap of $3,380.00, a P/E ratio of -18.14 and a beta of 2.50. GW Pharmaceuticals PLC- has a one year low of $92.65 and a one year high of $143.37. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.47 and a current ratio of 7.59.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings data on Monday, December 4th. The biopharmaceutical company reported ($2.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.45). GW Pharmaceuticals PLC- had a negative return on equity of 40.42% and a negative net margin of 1,607.85%. research analysts forecast that GW Pharmaceuticals PLC- will post -7.76 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. IHT Wealth Management LLC raised its holdings in shares of GW Pharmaceuticals PLC- by 18.0% during the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 100 shares during the period. Advisor Group Inc. raised its holdings in GW Pharmaceuticals PLC- by 10.7% in the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 145 shares during the period. BNP Paribas Arbitrage SA purchased a new stake in GW Pharmaceuticals PLC- in the 2nd quarter valued at about $163,000. Woodmont Investment Counsel LLC purchased a new stake in GW Pharmaceuticals PLC- in the 2nd quarter valued at about $201,000. Finally, Van Hulzen Asset Management LLC purchased a new stake in GW Pharmaceuticals PLC- in the 3rd quarter valued at about $205,000. Institutional investors and hedge funds own 74.52% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/05/gw-pharmaceuticals-plc-gwph-lowered-to-hold-at-bidaskclub.html.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.